300 related articles for article (PubMed ID: 17683868)
1. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Biochim Biophys Acta; 2007 Sep; 1776(1):1-9. PubMed ID: 17683868
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietic agents and the elderly.
Agarwal N; Prchal JT
Semin Hematol; 2008 Oct; 45(4):267-75. PubMed ID: 18809098
[TBL] [Abstract][Full Text] [Related]
3. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors.
Brines M
Blood Purif; 2010; 29(2):86-92. PubMed ID: 20093809
[TBL] [Abstract][Full Text] [Related]
5. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
Trkulja V
Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
[TBL] [Abstract][Full Text] [Related]
6. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
Tanaka T; Nangaku M
Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin and treatment of non-anemic conditions--cardiovascular protection.
Fliser D; Haller H
Semin Hematol; 2007 Jul; 44(3):212-7. PubMed ID: 17631185
[TBL] [Abstract][Full Text] [Related]
8. Current perspectives on protective roles of erythropoietin in cardiovascular system: erythropoietin receptor as a novel therapeutic target.
Kagaya Y; Asaumi Y; Wang W; Takeda M; Nakano M; Satoh K; Fukumoto Y; Shimokawa H
Tohoku J Exp Med; 2012 Jun; 227(2):83-91. PubMed ID: 22688525
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin use in CKD patients with cancer: to tread with caution?
Nayak-Rao S; McCormick B
J Nephrol; 2013; 26(5):829-35. PubMed ID: 24052463
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin stimulates spleen BMP4-dependent stress erythropoiesis and partially corrects anemia in a mouse model of generalized inflammation.
Millot S; Andrieu V; Letteron P; Lyoumi S; Hurtado-Nedelec M; Karim Z; Thibaudeau O; Bennada S; Charrier JL; Lasocki S; Beaumont C
Blood; 2010 Dec; 116(26):6072-81. PubMed ID: 20844235
[TBL] [Abstract][Full Text] [Related]
11. Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives.
Merchionne F; Dammacco F
Br J Haematol; 2009 Jul; 146(2):127-41. PubMed ID: 19388936
[TBL] [Abstract][Full Text] [Related]
12. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.
Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CR; Jelkmann W
Eur J Cancer; 2007 Feb; 43(3):510-9. PubMed ID: 17150352
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietins: a common mechanism of action.
Elliott S; Pham E; Macdougall IC
Exp Hematol; 2008 Dec; 36(12):1573-84. PubMed ID: 18922615
[TBL] [Abstract][Full Text] [Related]
15. The potential of erythropoietin for conferring cardioprotection complementing reperfusion.
Binbrek AS; Mittal B; Rao KN; Sobel BE
Coron Artery Dis; 2007 Nov; 18(7):583-5. PubMed ID: 17925614
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease.
Gupta N; Wish JB
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):345-350. PubMed ID: 29746307
[TBL] [Abstract][Full Text] [Related]
17. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
Mark TL; McKenzie RS; Fastenau J; Piech CT
Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
[TBL] [Abstract][Full Text] [Related]
18. [Pleiotropic effects of erythropoietin].
Kes P; Basić-Jukić N; Furić-Cunko V
Acta Med Croatica; 2009 Sep; 63 Suppl 1():46-53. PubMed ID: 20232551
[TBL] [Abstract][Full Text] [Related]
19. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.
Collino M; Thiemermann C; Cerami A; Brines M
Pharmacol Ther; 2015 Jul; 151():32-40. PubMed ID: 25728128
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives.
Debeljak N; Sytkowski AJ
Curr Pharm Des; 2008; 14(13):1302-10. PubMed ID: 18537654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
